We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

106 hedge funds and large institutions have $712M invested in ArriVent BioPharma in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 19

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

7% more funds holding

Funds holding: 99 → 106 (+7)

3% less capital invested

Capital invested by funds: $732M → $712M (-$19.7M)

3.21% less ownership

Funds ownership: 98.29% → 95.07% (-3.2%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

76% less call options, than puts

Call options by funds: $424K | Put options by funds: $1.75M

Holders
106
Holders Change
+7
Holders Change %
+7.07%
% of All Funds
1.39%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
18
Increased
46
Reduced
19
Closed
11
Calls
$424K
Puts
$1.75M
Net Calls
-$1.33M
Net Calls Change
-$1.33M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.7M
3
IAM
Infinitum Asset Management
Florida
+$8.84M
4
UBS Group
UBS Group
Switzerland
+$8.08M
5
Morgan Stanley
Morgan Stanley
New York
+$5.71M

Top Sellers

Rank Fund Capital Flow
1
HLAM
Hidden Lake Asset Management
New York
-$5.75M
2
Squarepoint
Squarepoint
New York
-$1.49M
3
WAM
Weiss Asset Management
Massachusetts
-$1.17M
4
Verition Fund Management
Verition Fund Management
Connecticut
-$814K
5
Citadel Advisors
Citadel Advisors
Florida
-$733K
Name Holding Trade Value Shares
Change 		Change in
Stake
HA
1
HHLR Advisors
Cayman Islands
$82.7M – – –
IAM
2
Infinitum Asset Management
Florida
$71.4M +$8.84M +450,000 +13%
SCM
3
Suvretta Capital Management
New York
$68.3M +$5.71M +290,664 +9%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$62.9M +$26.5M +1,349,480 +66%
O
5
OrbiMed
New York
$55.9M – – –
BlackRock
6
BlackRock
New York
$37.8M +$4.08M +207,762 +11%
Vanguard Group
7
Vanguard Group
Pennsylvania
$37.4M +$10.7M +545,991 +37%
OCA
8
Octagon Capital Advisors
New York
$36.4M +$491K +25,000 +1%
NHAS
9
Novo Holdings A/S
Denmark
$35.8M +$1.38M +70,000 +4%
SI
10
Sofinnova Investments
California
$31.3M – – –
GCGM
11
General Catalyst Group Management
Massachusetts
$27.6M – – –
State Street
12
State Street
Massachusetts
$19M +$5.64M +286,836 +39%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$13.2M +$2.36M +120,270 +20%
HH
14
HSG Holding
Hong Kong
$13M – – –
SL
15
Siren LLC
Connecticut
$12.9M – – –
F1I
16
Fund 1 Investments
Puerto Rico
$11.4M +$1.8M +91,456 +17%
UBS Group
17
UBS Group
Switzerland
$9.18M +$8.08M +411,013 +475%
Goldman Sachs
18
Goldman Sachs
New York
$7.97M +$1.82M +92,743 +27%
CLG
19
Cooperman Leon G
$7.77M – – –
Morgan Stanley
20
Morgan Stanley
New York
$7.23M +$5.71M +290,668 +287%
HLAM
21
Hidden Lake Asset Management
New York
$5.79M -$5.75M -292,815 -48%
WP
22
Woodline Partners
California
$5.48M +$2.95M +150,000 +102%
Millennium Management
23
Millennium Management
New York
$5.28M +$2.16M +109,935 +62%
Franklin Resources
24
Franklin Resources
California
$4.73M +$5.04M +256,422 New
Charles Schwab
25
Charles Schwab
California
$4.49M +$1.09M +55,284 +29%
1
2 3 4 5

AVBP Hedge Fund Activity: Q3 2025 in Review

106 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q3 2025, worth a combined $712M — down 2.7% from $732M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new AVBP positions and 11 closed out — a net gain of 7 holders — while 46 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $26.5M. The largest seller was Hidden Lake Asset Management, cutting an estimated $5.75M.

  • 106 institutional investors held ArriVent BioPharma (AVBP) as of Q3 2025, up from 99 in Q2 2025.
  • Funds reported $712M of ArriVent BioPharma stock for Q3 2025, down 2.7% quarter-over-quarter.
  • 18 funds opened new ArriVent BioPharma positions in Q3 2025 and 11 closed out, a net change of +7 holders.
  • The largest ArriVent BioPharma buyer in Q3 2025 was Fidelity Investments, an estimated $26.5M added.
  • The largest ArriVent BioPharma seller in Q3 2025 was Hidden Lake Asset Management, an estimated $5.75M sold.

Based on aggregated 13F filings for Q3 2025.